In the BioHarmony Drug Report Database

"Preview" Icon

Fulvestrant

Faslodex, Fulvestrant (fulvestrant) is a small molecule pharmaceutical. Fulvestrant was first approved as Faslodex on 2002-04-25. It is used to treat breast neoplasms in the USA. It has been approved in Europe to treat breast neoplasms. The pharmaceutical is active against estrogen receptor beta and estrogen receptor. In addition, it is known to target G-protein coupled estrogen receptor 1. Faslodex’s patents are valid until 2034-05-17 (FDA).

 

Trade Name

 

Faslodex
 

Common Name

 

fulvestrant
 

ChEMBL ID

 

CHEMBL1358
 

Indication

 

breast neoplasms
 

Drug Class

 

Estrogen antagonists

Image (chem structure or protein)

Fulvestrant structure rendering